Better Imaging of Cancer with Monoclonal Antibody Fragments
Author Information
Author(s): M. Gerretsen, J.J. Quak, J.S. Suhl, M. van Walsum, C.J.L.M. Meijer, G.B. Snow, G.A.M.S. van Dongen
Primary Institution: Free University Hospital Amsterdam
Hypothesis
Can the F(ab')2 fragment of monoclonal antibody E48 provide superior localization and imaging in cancer xenografts compared to the full IgG form?
Conclusion
The E48 F(ab')2 fragment showed significantly better tumor localization and imaging capabilities than the E48 IgG in xenograft models.
Supporting Evidence
- E48 IgG showed a mean tumor uptake of 11.9% at day 1, increasing to 14.6% at day 6.
- E48 F(ab')2 had a tumor to blood ratio of 13.6 at day 1, reaching 54.2 by day 6.
- In VX-A431 bearing mice, E48 F(ab')2 showed preferential localization in tumor tissue.
- Imaging with E48 F(ab')2 allowed visualization of tumors without background activity at day 1.
Takeaway
Scientists tested a special type of antibody to see if it could find and show cancer better than a regular antibody, and it worked much better!
Methodology
The study involved injecting radiolabelled monoclonal antibodies into mice with cancer and measuring how well they localized in tumors over several days.
Limitations
The study was conducted in mice, which may not fully represent human responses.
Participant Demographics
Female nude mice, 8-10 weeks old.
Want to read the original?
Access the complete publication on the publisher's website